Nav: Home

Three years and counting on atezolizumab for stage 4 CRC patient, Rodney Bearfoot

April 18, 2016

A symposium presented at the American Association for Cancer Research Annual Meeting 2016 offers updated results on the ongoing phase 1b clinical trial of anti-PDL1 immunotherapy atezolizumab in advanced stage colorectal cancer patients. Treated at the University of Colorado Cancer Center, one of the earliest trial participants is Rodney Bearfoot, who remains on trial with stable disease three years after being diagnosed with stage 4 colon cancer.

"We believe that tumor shrinkage isn't the only measure of successful cancer immunotherapy. In this case and others, the long term control of advanced colorectal cancer is a goal unto itself," says S. Gail Eckhardt, MD, FASCO, associate director for translational research at the University of Colorado Cancer Center.

The drug works by reinitiating the immune system's ability to recognize and destroy tumor tissue. Specifically, atezolizumab is one in a promising class of drugs known as PDL1 inhibitors. When the PDL1 receptor on a tumor cell's surface binds the protein PD-1, the interaction results in signaling that protects the cell against destruction by the immune system's T lymphocytes. Atezolizumab binds to PDL1 receptors, blocking the receptors' ability to bind PD-1 and thus reopening cells to immune system attack.

Atezolizumab was granted Breakthrough Therapy Designation by the FDA for the treatment of metastatic bladder cancer. The drug is also showing promising early results in clinical trials of breast cancer, non-small cell lung cancer, renal cell carcinoma and melanoma.

The current study reports results of 23 patients with metastatic colorectal cancer. Fifty-two percent of patients responded to treatment, which also included the chemotherapy FOLFOX and the anti-VEGF therapy bevacizumab. Median progression free survival was 14.1 months with a median duration of response of 11.4 months.

"I've been on the study so long, they went ahead and named it atezolizumab," says Bearfoot. "I had really hoped that they would have named the drug something that I could have pronounced!"

Bearfoot was diagnosed with colon cancer in 2008 and was treated with chemotherapy. In 2010 metastases were found in his lungs. At that point, Bearfoot became a patient with Eckhardt at the CU Cancer Center and underwent further chemotherapies that controlled his disease until 2013. Unfortunately, the tumor again started to progress and Bearfoot became eligible for the phase 1b clinical trial of atezolizumab.

"It's been more than three years and he is still on study," says Eckhardt.

"It amazes me that I have been blessed with such good fortune to be six years away from my stage 4 diagnosis," Bearfoot says. "I retired shortly after that diagnosis and have been working on all the items I put off during my working career."

Eckhardt describes another study participant who, with stage 4 colorectal cancer in his early 30s, continues to work fulltime. "You would never know he has cancer," Eckhardt says.

While many other types of cancer including lung, renal and melanoma have responded dramatically to immune therapies, several gastrointestinal cancers have been resistant, potentially decreasing interest in continued testing of immunotherapies in this population.

However, Eckhardt points out that, "It is well established in colorectal cancer that many regimens that offer overall survival benefit lead to disease stability and not shrinkage. While fewer patients have experienced tumor shrinkage, many of us that specialize in GI cancer are quite impressed with how long CRC patients have been on this study and are working together to move ahead with research in this area. This study update provides potential biomarkers that might help identify CRC patients that will benefit from immunotherapy, like Mr. Bearfoot."

University of Colorado Anschutz Medical Campus

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...